BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 7409232)

  • 1. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.
    Fotherby K; Saxena BN; Shrimanker K; Hingorani V; Takker D; Diczfalusy E; Landgren BM
    Fertil Steril; 1980 Aug; 34(2):131-9. PubMed ID: 7409232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
    Contraception; 1978 May; 17(5):395-406. PubMed ID: 657807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-a-month estrogen/progestogen injectables.
    D'arcangues C
    Entre Nous Cph Den; 1991 Dec; (19):15. PubMed ID: 12222332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of sustained release systems.
    Fotherby K
    J Steroid Biochem; 1979 Jul; 11(1B):457-9. PubMed ID: 491616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
    Moore LL; Valuck R; McDougall C; Fink W
    Contraception; 1995 Oct; 52(4):215-9. PubMed ID: 8605778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
    Bassol S; Hernandez C; Nava MP; Trujillo AM; Luz de la Cruz D
    Contraception; 1995 May; 51(5):307-11. PubMed ID: 7628206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depo Provera: a profile of current users.
    Jarman H; Kovacs GT; Westcott M
    Aust N Z J Obstet Gynaecol; 1990 Feb; 30(1):74-6. PubMed ID: 2140675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prolonged-action contraceptives].
    Alipov VI; Korkhov VV
    Akush Ginekol (Mosk); 1987 Sep; (9):7-8. PubMed ID: 3322079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Return of fertility in women discontinuing injectable contraceptives.
    Fotherby K; Howard G
    J Obstet Gynaecol (Lahore); 1986 Apr; 6 Suppl 2():S110-5. PubMed ID: 12315276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of injectable formulations of contraceptive steroids in obese and thin women.
    Fotherby K; Koetsawang S
    Contraception; 1982 Jul; 26(1):51-8. PubMed ID: 7128134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.